Clinical trial
ACP-196, a Btk Inhibitor, for Treatment of Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
This study is evaluating two dosing regimens, the safety, and efficacy of a new Bruton tyrosine kinase (Btk) inhibitor, ACP-196, for the treatment of subjects with Relapsed or Refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma.
| Category | Value |
|---|---|
| Study start date | 2014-04-10 |